Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT-Reference-Cited by-同舟云学术

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Published:2024-01-22 Issue:4 Volume:59 Page:479-488
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Salas María Queralt^ORCID,Eikema Diderik-Jan,Koster Linda,Maertens Johan,Passweg Jakob^ORCID,Finke Jürgen^ORCID,Broers Annoek E. C.,Koc Yener,Kröger Nicolaus^ORCID,Ozkurt Zubeyde Nur,Pascual-Cascon María Jesús,Platzbecker Uwe,Van Gorkom Gwendolyn,Schroeder Thomas^ORCID,López-Lorenzo José Luis,Martino Massimo^ORCID,Chiusolo Patrizia^ORCID,Kaufmann Martin,Onida Francesco,Gurnari Carmelo^ORCID,Scheid Christof,Drozd-Sokolowska Joanna,Raj Kavita^ORCID,Robin Marie^ORCID,McLornan Donal P.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-023-02159-1.pdf

Reference29 articles.

1. Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235–40.

2. Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant. 2023;58:647–58.

3. Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, et al. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2022;57:768–74.

4. Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, et al. Post-transplant cyclophosphamide combined with anti-thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2021;144:66–73.

5. Kanakry CG, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497–505.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome;Bone Marrow Transplantation;2024-07-08

2. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy;Bone Marrow Transplantation;2024-05-07